Welcome to the tag category page for Glycemic Control!
SGLT, or sodium-glucose transport proteins, are a family of glucose transporters found in the intestinal mucosa and renal proximal convoluted tubules. SGLT2 inhibitors are a class of medication used to treat type 2 diabetes by blocking the reabsorption of glucose in the kidneys and promoting its excretion in the urine. Common examples of SGLT2 inhibitors include Invokana, Farxiga, Jardiance, and Steglatro. SGLT1 is responsible for glucose absorption in the small intestine and reabsorbing about 3% of the filtered glucose load in the renal proximal tubule segment 3. SGLT2, on the other hand, is responsible for the majority of glucose reuptake in the tubular system of the kidney. SGLT2 inhibitors are versatile medications with glycemic and nonglycemic benefits that help lower blood sugar levels in adults with type 2 diabetes.
